ArticleFrontiers in oncology2024

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

Alexander Englisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.